| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:05 | HYTN bringt seine Cannabisprodukte erfolgreich in Deutschland auf den Markt und nimmt Nachbestellung entgegen | 1.309 | IR-WORLD | VANCOUVER, British Columbia, 27. März 2026 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
pharmazeutischer Hersteller, der sich... ► Artikel lesen | |
| 08:46 | Novo Nordisk Aktie: Bricht der Kurs weiter ein oder dreht er jetzt um? | 1.222 | FinanzNachrichten.de | © Foto: 2026 Novo Nordisk A/SNoch vor wenigen Jahren war Novo Nordisk eine der heißesten Aktien der Welt. Der dänische Pharmakonzern hinter Ozempic und Wegovy galt als Goldesel, und der Kurs schoss... ► Artikel lesen | |
| Fr | Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2025 | 510 | GlobeNewswire (Europe) | March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals... ► Artikel lesen | |
| Fr | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.03.2026 | 473 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.03.2026.ISIN NameCA98420Q3061 XORTX... ► Artikel lesen | |
| Fr | InMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance | 399 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying... ► Artikel lesen | |
| 12:06 | Bristol Myers Squibb: Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy (xanomeline and trospium chloride) | 348 | Business Wire | High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase... ► Artikel lesen | |
| 16:06 | Sanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session | 286 | GlobeNewswire (Europe) | AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed... ► Artikel lesen | |
| Fr | UCB SA Reports Long-Term Bimzelx Data In Hidradenitis Suppurativa | 257 | AFX News | BRUSSELS (dpa-AFX) - UCB S.A. (UCBJY) announced on Friday that it has presented new post hoc data regarding Bimzelx (bimekizumab) at the American Academy of Dermatology Annual Meeting 2026 held... ► Artikel lesen | |
| 16:06 | Galderma SA: AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis | 244 | Business Wire |
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a... ► Artikel lesen | |
| Fr | HYTN Innovations Inc.: HYTN Successfully Releases Cannabis Products in Germany and Accepts Reorder | 100 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, March 27, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or the "Company"), a pharmaceutical manufacturer specializing... ► Artikel lesen | |
| Fr | PMGC Holdings Inc.: NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments | 100 | GlobeNewswire (Europe) | NEWPORT BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc.'s (NASDAQ: ELAB) ("PMGC," "we," or "our") wholly owned subsidiary, NorthStrive Biosciences Inc. ("Northstrive Biosciences")... ► Artikel lesen | |
| Fr | Diamyd Medical AB: Diamyd Medical reports negative interim results of Phase 3 DIAGNODE-3 trial | 73 | GlobeNewswire (Europe) | Diamyd Medical today announced the completion of a pre-specified interim efficacy analysis on C-peptide in the ongoing pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals... ► Artikel lesen | |
| 00:36 | Quantum Biopharma Provides Corporate Update | 71 | GlobeNewswire (Europe) | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 27, 2026... ► Artikel lesen | |
| 17:48 | Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis | 51 | AFX News | PARIS (dpa-AFX) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trials-COAST 1, COAST 2, and SHORE-evaluating amlitelimab, a fully human non-T cell... ► Artikel lesen | |
| Fr | iAnthus Capital Holdings, Inc.: iAnthus Reports Fiscal Fourth Quarter and Full Year 2025 Financial Results | 48 | GlobeNewswire (Europe) | NEW YORK and TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. ("iAnthus" or the "Company") (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| PERRIGO | 8,100 | 0,98 | +12,10 % | 0,29 | 02.03.2026 | |
| NOVO NORDISK | 30,465 | 1,57 | +5,15 % | 7,95 | 27.03.2026 | |
| SANOFI | 81,82 | 3,92 | +4,79 % | 4,12 | 05.05.2026 | |
| BRISTOL-MYERS SQUIBB | 51,10 | 2,16 | +4,23 % | 0,63 | 02.04.2026 | |
| TSUMURA | 19,900 | 0,78 | +3,92 % | 76,00 | 30.03.2026 | |
| NIPPON KAYAKU | 9,700 | 0,33 | +3,40 % | 30,00 | 30.03.2026 | |
| EISAI | 26,000 | 0,87 | +3,35 % | 80,00 | 30.03.2026 | |
| CHUGAI PHARMACEUTICAL | 45,680 | 1,48 | +3,24 % | 66,00 | 29.06.2026 | |
| ONO PHARMACEUTICAL | 13,300 | 0,43 | +3,23 % | 40,00 | 30.03.2026 | |
| GSK | 23,670 | 0,76 | +3,21 % | 0,18 | 19.02.2026 |